Ixabepilone (Ixempra)

Description

Ixabepilone is an epothilone B analog chemotherapy agent that belongs to the microtubule-stabilizing class of cytotoxic drugs. While FDA-approved for metastatic breast cancer, it has been evaluated in colorectal cancer clinical trials as a potential treatment option for metastatic disease. The drug works by binding to beta-tubulin and stabilizing microtubules, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Its use in colorectal cancer represents an off-label application based on its broad cytotoxic activity against solid tumors.

Mechanism of Action

Ixabepilone binds directly to beta-tubulin subunits in microtubules, causing stabilization of the microtubule structure and preventing normal microtubule dynamics required for cell division. This mechanism leads to mitotic arrest in the G2/M phase of the cell cycle, ultimately triggering apoptotic cell death. Unlike taxanes, ixabepilone maintains activity in multidrug-resistant tumor cells and those with beta-tubulin mutations.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials